Clinical Trials Logo

Ischemia clinical trials

View clinical trials related to Ischemia.

Filter by:

NCT ID: NCT06085378 Not yet recruiting - Type 2 Diabetes Clinical Trials

Efficacy and Safety of Urinary Kallidinogenase in the Treatment of Acute Ischemic Stroke Combined With Type 2 Diabetes Mellitus

TK-SEEK
Start date: January 1, 2024
Phase: N/A
Study type: Interventional

This study is a multicenter, randomized, double-blind, placebo parallel control study, aim to evaluate the efficacy and safety of human urinary kallidinogenase in the treatment of acute ischemic stroke with type 2 diabetes.

NCT ID: NCT06083961 Not yet recruiting - Clinical trials for Stroke, Acute Ischemic

The Effect of Early Administration of PCSK9 Inhibitor to Acute Ischemic Stroke Patients Associated With Atherosclerosis on the Stroke Prognosis and Lipid Profile

Start date: October 15, 2023
Phase: Phase 4
Study type: Interventional

The goal of this clinical trial is to test the effect of proprotein convertase subtilisin/kexin type 9 (PCSK9 inhibitors) in acute ischemic stroke patients associated with atherosclerosis by investigating 1. the change in lipid profile compared to baseline results 2. the effects on prognosis of stroke The participants will be given PCSK9 inhibitor right after confirmation of acute ischemic stroke, and the investigators will compare the results to the control group, whom are acute ischemic stroke patients treated with conventional lipid lowering therapy, statin and/or ezetimibe.

NCT ID: NCT06082466 Recruiting - Clinical trials for Peripheral Arterial Occlusive Disease

FRAMED Infrainguinal Venous Bypass Versus Conventional Autologous Bypass Trial

Framed IVB
Start date: September 11, 2023
Phase: N/A
Study type: Interventional

The purpose of this clinical trial is to analyze patency after autologous infrainguinal bypass surgery in patients receiving a venous conduit versus a covered venous conduit.

NCT ID: NCT06081283 Recruiting - Stroke Clinical Trials

Antiseizure Medication in Seizure Networks at Early Acute Brain Injury

Start date: November 20, 2023
Phase: Phase 4
Study type: Interventional

The goal of this clinical trial is to explore the effect of FDA-approved antiseizure drugs in the brain connectivity patterns of severe and moderate acute brain injury patients with suppression of consciousness. The main questions it aims to answer are: - Does the antiseizure medication reduce the functional connectivity of seizure networks, as identified by resting state functional MRI (rs-fMRI), within this specific target population? - What is the prevalence of seizure networks in patients from the target population, both with EEG suggestive and not suggestive of epileptogenic activity? Participants will have a rs-fMRI and those with seizure networks will receive treatment with two antiseizure medications and a post-treatment rs-fMRI. Researchers will compare the pretreatment and post-treatment rs-fMRIs to see if there are changes in the participant's functional connectivity including seizure networks and typical resting state networks.

NCT ID: NCT06080308 Recruiting - Liver Injury Clinical Trials

Liver Ischemia-reperfusion Injury and Clinical Data Analysis

Start date: October 10, 2023
Phase:
Study type: Observational

Searching for new targets for the diagnosis and treatment of liver ischemia-reperfusion injury.

NCT ID: NCT06079255 Not yet recruiting - Carbon Dioxide Clinical Trials

Ischemia Detection During Development of Acute Compartment Syndrome

IDEA
Start date: December 15, 2023
Phase:
Study type: Observational

This is an open, observational, prospective, descriptive, single-centre study including 60 patients. The study is designed to investigate if IscAlert sensor system can be used for reliable and continuous tissue carbon dioxide (pCO2)- and temperature monitoring in muscular tissue in lower extremity in patients at risk of developing acute compartment syndrome.

NCT ID: NCT06078995 Recruiting - Ischemic Stroke Clinical Trials

Tenecteplase Thrombolytic Therapy for Acute Ischemic Stroke in China

TTT-AIS CHINA
Start date: April 2, 2023
Phase:
Study type: Observational

The objective of the study is to investigate the effectiveness and safety of rhTNK-tPA in acute ischemic stroke patients within 4.5 hours of symptom onset in a real-world clinical setting.

NCT ID: NCT06078215 Recruiting - Clinical trials for Acute Ischemic Stroke

CERebrolysine Effect on Blood-brain Barrier in acUte Ischemic Stroke

CERBERUS
Start date: January 10, 2023
Phase: Phase 4
Study type: Interventional

The study investigates whether Cerebrolysin stabilizes blood-brain barrier integrity in a manner that can be monitored using serum levels of the principal tight junction proteins, e.g., occludin (OCL), claudin-5 (CLN), and zonula occludens-1 (ZO-1), or other molecules known to be involved in BBB degradation, e.g., S100B and whether it protects against hemorrhagic transformation in ischemic stroke patients after reperfusion therapy (i.e. thrombolysis and/or mechanical thrombectomy).

NCT ID: NCT06077305 Not yet recruiting - Ischemic Stroke Clinical Trials

A Registry Study of Microcirculation Disorder After Cerebral Small Vessel Disease and Ischemic Stroke

MODEST
Start date: October 30, 2023
Phase:
Study type: Observational

This study aims to construct a registry platform for microcirculatory disorders in a large sample of Chinese patients with cerebral small vessel disease and ischemic stroke; To explore the role of microcirculatory disorders in different types of cerebral small vessel disease and iachemic stroke, as well as their pathogenesis, severity, and prognosis; And to research on the drug treatment of microcirculatory disorders for cerebral small vessel disease and stroke in the real world.

NCT ID: NCT06076122 Recruiting - Stroke Clinical Trials

Salicornia for Neurovascular Health Improve

Start date: September 15, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is evaluate the effect and safety of the administration of a food supplement based on halophyte plant extracts versus placebo in the neurovascular healthy.